On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Zacks.com on MSN5h
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...
Irish Independent on MSN17h
Profits drop at Botox plant in Westport as revenues down by 4pcPre-tax profits at AbbVie’s global production facility for Botox, in Westport, last year declined by 27pc to $1.1bn (€1.04bn). New accounts filed by Allergan Pharmaceuticals Ireland UC show that the ...
November is National Caregivers Month. Now is a good time for employers to increase support for their working caregiver population.
2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...
Dr. Meijing Wu is described by friends and colleagues as a distinguished biostatistician and “a kind and generous friend who ...
AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback